Cutiss AG develops personalized bio-engineered tissue therapy for skin surgery. The company focuses on innovation in regenerative medicine, aiming to provide patients who suffer from large skin injuries and defects with personalized skin tissue therapy.

Cutiss

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

Our mission: to give patients back more of their own skin to make them well again. 

CUTISS is a Swiss clinical-stage life sciences company focussed on regenerative medicine, skin tissue engineering, and skin pigmentation. 

We are developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.

Our lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase 2 clinical trials in Switzerland and the European Union. It has Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.

CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. 

Our company’s knowledge in skin bio-engineering and biology offers other growth opportunities in regenerative medicine, and also beyond the medical domain. 

Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) / University Children’s Hospital. We successfully exited the Wyss Zurich accelerator in 2022.

Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over CHF 90 million from private investors, family offices and public bodies.

Innosuisse

Government of France

UZH Life Sciences Fund

Yellowstone Holding

Zürcher Kantonal Bank

Giammaria Giuliani

The Wyss Foundation

Shiloh Advisors

CUTISS AG

We're excited to be included in L'Agefi's list of 10 game-changing Swiss innovations! 🌟 Read the full article "CUTISS gives burn victims new skin" to get the latest news about our work in revolutionizing skin surgery.

Thank you to Sophie Marenne for the visit and wonderful article

AGEFI, Nouvelle Agence Économique et Financière #innovation #swisstech #regenerativemedicine #tissueengineering #seriesC #clinicaltrials

Soaring summer temperatures in regions like Nevada and Phoenix can lead to serious skin contact burns and injuries from hot pavements and surfaces. About 40% of patients require skin surgery to remove damaged tissue and cover the area with a skin graft. Some spend weeks in the hospital recovering.
 
It’s difficult to ignore the severe impacts that such high temperatures can have on regular people. The available treatment options for skin injuries need to expand.
 
We're committed to advancing skin regenerative medicine to improve skin surgery and recovery outcomes for severe burn patients.
 
Read the full New York Times article:
https://lnkd.in/dTAvEbwF

In 2021, the total incident population of burn injuries across the 7MM was approximately 2 million, with the US accounting for 662,000 cases. Additionally, the Burns market is projected to experience substantial growth with a significant CAGR by 2032. CUTISS AG is leading the scene with personalized tissue engineering to address the unmet needs in burns and beyond. #treatmentforburns #regenerativemedicine #automation

A significant milestone in pediatric burn care in Italy – the inauguration of the new pediatric burn center at Santobono Hospital in Naples, a new center of excellence at European level! 
 
Since 2021, Santobono has been the coordinating center in Italy for our Phase 2 clinical trial of denovoSkin™, CUTISS’ bioengineered autologous human skin tissue. Notably, Santobono was the first pediatric center in the world to perform a denovoSkin™ transplant in a neonate.
 
We feel incredibly proud and honored to collaborate on this groundbreaking project with Marcello Zamparelli, underscoring our commitment to change the status quo in skin surgery and improve patient outcomes with cutting-edge regenerative medicine. 
 
The new facility will enable quicker interventions for patients and allow continuous control, monitoring, and verification of the therapies and innovative treatments they receive.
 
Burns are the 3rd leading cause of death in children. In Campania region of Italy, between 2022 and 2023, 120 young patients were treated. Of these, 70% had severe or very severe burns; 80% required surgical hospitalizations. It is in this context that the new pediatric burn center at Santobono-Pausilipon was inaugurated yesterday.
 
Watch snippets of the La Presse reportage below and for more details read on here: 
Rai - Radiotelevisione Italiana: https://lnkd.in/eu9RTWck
LaPresse SpA: https://lnkd.in/e443sPTH 
ANSA news agency: https://lnkd.in/e_VXv4Mu
Il Mattino: https://lnkd.in/eEVRHhWX
 
 #PediatricCare #RegenerativeMedicine #Innovation #BurnTreatment Regione Campania Comune di Napoli Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon

We’re driven to change the status quo in skin surgery. 
 
At the Swiss Biotech Day this week, we were among the selected companies in the clinical stage category invited to present. Our CEO Daniela Marino took the stage to share CUTISS’s recent milestones and our next last-stage clinical steps, and to illustrate our approach to revolutionize skin surgery. 
 
Let’s keep pushing the boundaries of what's possible in regenerative medicine!
 
#SwissBiotechDay #RegenerativeMedicine #Biotech #Innovation  #BioEngineering

🚀 Clinical trials update from CUTISS!

We’re excited to announce a positive interim analysis on the efficacy of our lead product denovoSkin™ (versus standard of care) from the Phase 2 clinical trial in reconstructive skin surgery. 

This trial focuses on pediatric, adolescent and adult patients requiring skin grafts in skin reconstructive procedures. denovoSkin™ aims to provide a solution to reduce scarring and therefore improve healing outcomes​.

“These results confirm our mission to provide access to denovoSkin™ beyond burns, changing the status quo in skin surgery globally,” said Daniela Marino, CEO of CUTISS. “We extend our heartfelt gratitude to all involved in this multicentric trial across Switzerland, Italy, and the Netherlands.”

The full data analysis with one-year follow-up results is expected in early 2025. 

Read our press release for more details: https://lnkd.in/ektSC2ij

#RegenerativeMedicine #Innovation #Healthcare #ClinicalTrials #SkinSurgery

Metric
Company Name	Cutiss	Campus Biotech
Symbol
MSH ID	SWISS:CUTISS	CH:CAMPUSBIOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences
Country	CH	CH
Stage
Employee Count	58
Website	cutiss.swiss	campusbiotech.ch
LinkedIn	cutiss-ag	campus-biotech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.59
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SWISS:CUTISS

Cutiss

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue